Are lithium effects dependent on genetic/epigenetic architecture?

Neuropsychopharmacology. 2019 Jan;44(1):228. doi: 10.1038/s41386-018-0194-6.

Authors

Consuelo Walss-Bass¹, Gabriel R Fries²

Affiliations

¹ Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA. Consuelo.walssbass@uth.tmc.edu.
² Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.

No abstract available

Publication types

News
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antimanic Agents / therapeutic use*
Bipolar Disorder / drug therapy*
Bipolar Disorder / genetics
Epigenesis, Genetic
Humans
Lithium / therapeutic use*
Pharmacogenetics
Proto-Oncogene Proteins c-akt / genetics
Treatment Outcome

Substances

Antimanic Agents
Lithium
Proto-Oncogene Proteins c-akt

Grants and funding